Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy Results from the I‑SPY2 Clinical Trial Por [email protected] Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy Results from the I‑SPY2 Clinical Trial Read More »
Immediate breast reconstruction by prepectoral polyurethane implant: Preliminary results of the prospective study PreQ-20 Por [email protected] Immediate breast reconstruction by prepectoral polyurethane implant: Preliminary results of the prospective study PreQ-20 Read More »
Significantly reducing implant loss rates in immediate implant-based breast reconstruction: A protocol and completed audit of quality assurance Por [email protected] Significantly reducing implant loss rates in immediate implant-based breast reconstruction: A protocol and completed audit of quality assurance Read More »
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy Por [email protected] TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy Read More »
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 Por [email protected] Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 Read More »
FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer Por [email protected] FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer Read More »
Differential prognostic value of residual nodal burden in breast cancer subtypes Por [email protected] Differential prognostic value of residual nodal burden in breast cancer subtypes Read More »
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) Por [email protected] A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) Read More »
Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study Por [email protected] Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study Read More »
Inframammary versus Periareolar Incision: A Comparison of Early Complications in Nipple-sparing Mastectomy Por [email protected] Inframammary versus Periareolar Incision: A Comparison of Early Complications in Nipple-sparing Mastectomy Read More »
Cryoablation Without Excision for Early‑Stage Breast Cancer:ICE3 Trial 5‑Year Follow‑Up on Ipsilateral Breast Tumor Recurrence Por Adson Machado Cryoablation Without Excision for Early‑Stage Breast Cancer:ICE3 Trial 5‑Year Follow‑Up on Ipsilateral Breast Tumor Recurrence Read More »
PEARL: A Phase Ib/II Biomarker Study of Adding RadiationTherapy to Pembrolizumab Before NeoadjuvantChemotherapy in Human Epidermal Growth Factor Receptor2–Negative Breast Cancer Por Adson Machado PEARL: A Phase Ib/II Biomarker Study of Adding RadiationTherapy to Pembrolizumab Before NeoadjuvantChemotherapy in Human Epidermal Growth Factor Receptor2–Negative Breast Cancer Read More »
